Disease severity in hospitalized COVID-19 patients: comparing routine surveillance with cohort data from the LEOSS study in 2020 in Germany

the LEOSS Study Group

doi:10.1186/s12879-023-08035-z

Disease severity in hospitalized COVID-19 patients: comparing routine surveillance with cohort data from the LEOSS study in 2020 in Germany

the LEOSS Study Group

Institut für Medizinische Mikrobiologie

2 Zitate (Scopus)

Abstract

Introduction: Studies investigating risk factors for severe COVID-19 often lack information on the representativeness of the study population. Here, we investigate factors associated with severe COVID-19 and compare the representativeness of the dataset to the general population. Methods: We used data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) of hospitalized COVID-19 patients diagnosed in 2020 in Germany to identify associated factors for severe COVID-19, defined as progressing to a critical disease stage or death. To assess the representativeness, we compared the LEOSS cohort to cases of hospitalized patients in the German statutory notification data of the same time period. Descriptive methods and Poisson regression models were used. Results: Overall, 6672 hospitalized patients from LEOSS and 132,943 hospitalized cases from the German statutory notification data were included. In LEOSS, patients above 76 years were less likely represented (34.3% vs. 44.1%). Moreover, mortality was lower (14.3% vs. 21.5%) especially among age groups above 66 years. Factors associated with a severe COVID-19 disease course in LEOSS included increasing age, male sex (adjusted risk ratio (aRR) 1.69, 95% confidence interval (CI) 1.53–1.86), prior stem cell transplantation (aRR 2.27, 95% CI 1.53–3.38), and an elevated C-reactive protein at day of diagnosis (aRR 2.30, 95% CI 2.03–2.62). Conclusion: We identified a broad range of factors associated with severe COVID-19 progression. However, the results may be less applicable for persons above 66 years since they experienced lower mortality in the LEOSS dataset compared to the statutory notification data.

Originalsprache	Englisch
Aufsatznummer	89
Zeitschrift	BMC Infectious Diseases
Jahrgang	23
Ausgabenummer	1
Seiten (von - bis)	89
DOIs	https://doi.org/10.1186/s12879-023-08035-z
Publikationsstatus	Veröffentlicht - 10.02.2023

Fördermittel

The LEOSS registry was supported by the German Centre for Infection Research (DZIF) and the Willy Robert Pitzer Foundation. We express our deep gratitude to all study teams supporting the LEOSS study. The LEOSS registry was supported by the German Centre for Infection Research (DZIF) and the Willy Robert Pitzer Foundation. We express our deep gratitude to all study teams supporting the LEOSS study. The LEOSS study infrastructure group: Jörg Janne Vehreschild (Goethe University Frankfurt), Susana M. Nunes de Miranda (University Hospital of Cologne), Carolin E. M. Knoll (University Hospital of Cologne), Melanie Stecher (University Hospital of Cologne), Lisa Pilgram (Charité, Universitätsmedizin Berlin), Nick Schulze (University Hospital of Cologne), Sandra Fuhrmann (University Hospital of Cologne), Max Schons (University Hospital of Cologne), Annika Claßen (University Hospital of Cologne), Bernd Franke (University Hospital of Cologne) und Fabian Praßer (Charité, Universitätsmedizin Berlin). The LEOSS study group contributed at least 5 per mille to the analyses of this study: Christoph D. Spinner12, Maria Madeleine Rüthrich4, Julia Lanznaster5, Stefan Borgmann7, Kerstin Hellwig9, Maria Vehreschild13, Christian Hohmann14, Frank Hanses15, Kai Wille16, Bjoern-Erik Jensen17, Martin Hower18, Siegbert Rieg19, Juergen vom Dahl20, Jan Rupp21, Christoph Roemmele22, Nora Isberner23, Katja Rothfuss24, Lukas Eberwein25, Norma Jung26, Timm Westhoff27, Sebastian Dolff28, Richard Strauss29, Ingo Voigt30, Michael von Bergwelt-Baildon31, Uta Merle32, Christian Degenhardt33, Gernot Beutel34, Lorenz Walter35, Siri Göpel36, Beate Gruener37, Dominic Rauschning38, Janina Trauth39, Milena Milovanovic40, Katja de With41, Philipp Markart42, Jessica Rueddel43, Anette Friedrichs44, Jan Kielstein45, Lukas Tometten46, David Heigener47, Lars Wojtecki48, Joerg Schubert49, Wolfgang Guggemos50, Stefani Roeseler51, Mark Neufang52.4University Hospital Jena, Centre for Emergency Medicine, University Hospital Jena, Jena, Germany,5Hospital Passau, Department of Internal Medicine I, Hospital Passau, Passau, Germany,7Hospital Ingolstadt, Department of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany,9Catholic Hospital Bochum (St. Josef Hospital) Ruhr University Bochum, Department of Neurology, St. Josef-Hospital Bochum, Ruhr University Bochum, Bochum, Germany,12Technical University of Munich, Department of Internal Medicine II, School of Medicine, Technical University of Munich, University Hospital rechts der Isar, Munich, Germany,13University Hospital Frankfurt, Frankfurt, Germany,14Hospital Bremen-Center, Bremen, Germany,15University Hospital Regensburg, Regensburg, Germany,16Johannes Wesling Hospital Minden Ruhr University Bochum, Bochum, Germany,17University Hospital Duesseldorf, Duesseldorf, Germany,18Klinikum Dortmund gGmbH, Hospital of University Witten/Herdecke, Dortmund, Germany,19University Hospital Freiburg, Freiburg, Germany,20Hospital Maria Hilf GmbH Moenchengladbach, Moenchengladbach¸Germany,21University Hospital Schleswig–Holstein Luebeck, Luebeck, Germany,22University Hospital Augsburg, Augsburg, Germany,23University Hospital Wuerzburg, Wuerzburg, Germany,24Robert-Bosch-Hospital Stuttgart, Stuttgart, Germany,25Hospital Leverkusen, Leverkusen, Germany,26University Hospital Cologne, Cologne, Germany,27Marien Hospital Herne Ruhr University Bochum, Bochum, Germany,28University Hospital Essen, Essen, Germany,29University Hospital Erlangen, Erlangen, Germany,30Elisabeth Hospital Essen, Essen, Germany,31University Hospital Munich/ LMU, Munich, Germany,32University Hospital Heidelberg, Heidelberg, Germany,33Municipal Hospital Karlsruhe, Karlsruhe, Germany,34Medical School Hannover, Hannover, Germany,35Hospital St. Joseph-Stift Dresden, Dresden, Germany,36University Hospital Tuebingen, Tuebingen¸ Germany,37University Hospital Ulm, Ulm, Germany,38Bundeswehr Hospital Koblenz, Koblenz, Germany,39University Hospital of Giessen and Marburg, Germany,40Malteser Hospital St. Franziskus Flensburg, Flensburg, Germany,41University Hospital Dresden, Dresden, Germany,42Hospital Fulda, Fulda, Germany,43Sophien- and Hufeland Clinic Weimar, Weimar, Germany,44University Hospital Schleswig–Holstein Kiel, Kiel, Germany,45Hospital Braunschweig, Braunschweig¸ Germany,46Hospital Ernst von Bergmann, Potsdam, Germany,47Agaplesion Diakonie Hospital Rotenburg, Rotenburg, Germany,48Hospital Heiligen Geist Kempen, Kempen, Germany,49Elbland Hospital Riesa, Riesa, Germany,50Clinic Munich, Munich, Germany,51Hospital of the Augustinian Cologne, Cologne, Germany,52Evangelisches Hospital Saarbruecken, Saarbruecken, Germany.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

Coronavirus-Bezug

Forschung zu SARS-CoV-2 / COVID-19

Dokumente

10.1186/s12879-023-08035-z

Weitere Links

Zitieren

@article{cc0b3c2ad89a4b25a32c73a276fecabf,

title = "Disease severity in hospitalized COVID-19 patients: comparing routine surveillance with cohort data from the LEOSS study in 2020 in Germany",

abstract = "Introduction: Studies investigating risk factors for severe COVID-19 often lack information on the representativeness of the study population. Here, we investigate factors associated with severe COVID-19 and compare the representativeness of the dataset to the general population. Methods: We used data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) of hospitalized COVID-19 patients diagnosed in 2020 in Germany to identify associated factors for severe COVID-19, defined as progressing to a critical disease stage or death. To assess the representativeness, we compared the LEOSS cohort to cases of hospitalized patients in the German statutory notification data of the same time period. Descriptive methods and Poisson regression models were used. Results: Overall, 6672 hospitalized patients from LEOSS and 132,943 hospitalized cases from the German statutory notification data were included. In LEOSS, patients above 76 years were less likely represented (34.3\% vs. 44.1\%). Moreover, mortality was lower (14.3\% vs. 21.5\%) especially among age groups above 66 years. Factors associated with a severe COVID-19 disease course in LEOSS included increasing age, male sex (adjusted risk ratio (aRR) 1.69, 95\% confidence interval (CI) 1.53–1.86), prior stem cell transplantation (aRR 2.27, 95\% CI 1.53–3.38), and an elevated C-reactive protein at day of diagnosis (aRR 2.30, 95\% CI 2.03–2.62). Conclusion: We identified a broad range of factors associated with severe COVID-19 progression. However, the results may be less applicable for persons above 66 years since they experienced lower mortality in the LEOSS dataset compared to the statutory notification data.",

author = "\{the LEOSS Study Group\} and Uwe Koppe and Julia Schilling and Melanie Stecher and R{\"u}thrich, \{Maria Madeleine\} and Adine Marquis and Michaela Diercke and Martina Haselberger and Koll, \{Carolin E.M.\} and Michaela Niebank and Bettina Ruehe and Stefan Borgmann and Linus Grabenhenrich and Kerstin Hellwig and Lisa Pilgram and Spinner, \{Christoph D.\} and Thomas Paerisch and Julia Lanznaster and Maria Vehreschild and Christian Hohmann and Frank Hanses and Kai Wille and Jensen, \{Bjoern Erik\} and Martin Hower and Siegbert Rieg and \{vom Dahl\}, Juergen and Jan Rupp and Christoph Roemmele and Nora Isberner and Katja Rothfuss and Lukas Eberwein and Norma Jung and Timm Westhoff and Sebastian Dolff and Richard Strauss and Ingo Voigt and \{von Bergwelt-Baildon\}, Michael and Uta Merle and Christian Degenhardt and Gernot Beutel and Lorenz Walter and Siri G{\"o}pel and Beate Gruener and Dominic Rauschning and Janina Trauth and Milena Milovanovic and \{de With\}, Katja and Philipp Markart and Jessica Rueddel and Anette Friedrichs and Jan Kielstein",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = feb,

day = "10",

doi = "10.1186/s12879-023-08035-z",

language = "English",

volume = "23",

pages = "89",

journal = "BMC Infectious Diseases",

issn = "1471-2334",

publisher = "BioMed Central Ltd",

number = "1",

}

TY - JOUR

T1 - Disease severity in hospitalized COVID-19 patients

T2 - comparing routine surveillance with cohort data from the LEOSS study in 2020 in Germany

AU - the LEOSS Study Group

AU - Koppe, Uwe

AU - Schilling, Julia

AU - Stecher, Melanie

AU - Rüthrich, Maria Madeleine

AU - Marquis, Adine

AU - Diercke, Michaela

AU - Haselberger, Martina

AU - Koll, Carolin E.M.

AU - Niebank, Michaela

AU - Ruehe, Bettina

AU - Borgmann, Stefan

AU - Grabenhenrich, Linus

AU - Hellwig, Kerstin

AU - Pilgram, Lisa

AU - Spinner, Christoph D.

AU - Paerisch, Thomas

AU - Lanznaster, Julia

AU - Vehreschild, Maria

AU - Hohmann, Christian

AU - Hanses, Frank

AU - Wille, Kai

AU - Jensen, Bjoern Erik

AU - Hower, Martin

AU - Rieg, Siegbert

AU - vom Dahl, Juergen

AU - Rupp, Jan

AU - Roemmele, Christoph

AU - Isberner, Nora

AU - Rothfuss, Katja

AU - Eberwein, Lukas

AU - Jung, Norma

AU - Westhoff, Timm

AU - Dolff, Sebastian

AU - Strauss, Richard

AU - Voigt, Ingo

AU - von Bergwelt-Baildon, Michael

AU - Merle, Uta

AU - Degenhardt, Christian

AU - Beutel, Gernot

AU - Walter, Lorenz

AU - Göpel, Siri

AU - Gruener, Beate

AU - Rauschning, Dominic

AU - Trauth, Janina

AU - Milovanovic, Milena

AU - de With, Katja

AU - Markart, Philipp

AU - Rueddel, Jessica

AU - Friedrichs, Anette

AU - Kielstein, Jan

PY - 2023/2/10

Y1 - 2023/2/10

N2 - Introduction: Studies investigating risk factors for severe COVID-19 often lack information on the representativeness of the study population. Here, we investigate factors associated with severe COVID-19 and compare the representativeness of the dataset to the general population. Methods: We used data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) of hospitalized COVID-19 patients diagnosed in 2020 in Germany to identify associated factors for severe COVID-19, defined as progressing to a critical disease stage or death. To assess the representativeness, we compared the LEOSS cohort to cases of hospitalized patients in the German statutory notification data of the same time period. Descriptive methods and Poisson regression models were used. Results: Overall, 6672 hospitalized patients from LEOSS and 132,943 hospitalized cases from the German statutory notification data were included. In LEOSS, patients above 76 years were less likely represented (34.3% vs. 44.1%). Moreover, mortality was lower (14.3% vs. 21.5%) especially among age groups above 66 years. Factors associated with a severe COVID-19 disease course in LEOSS included increasing age, male sex (adjusted risk ratio (aRR) 1.69, 95% confidence interval (CI) 1.53–1.86), prior stem cell transplantation (aRR 2.27, 95% CI 1.53–3.38), and an elevated C-reactive protein at day of diagnosis (aRR 2.30, 95% CI 2.03–2.62). Conclusion: We identified a broad range of factors associated with severe COVID-19 progression. However, the results may be less applicable for persons above 66 years since they experienced lower mortality in the LEOSS dataset compared to the statutory notification data.

AB - Introduction: Studies investigating risk factors for severe COVID-19 often lack information on the representativeness of the study population. Here, we investigate factors associated with severe COVID-19 and compare the representativeness of the dataset to the general population. Methods: We used data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) of hospitalized COVID-19 patients diagnosed in 2020 in Germany to identify associated factors for severe COVID-19, defined as progressing to a critical disease stage or death. To assess the representativeness, we compared the LEOSS cohort to cases of hospitalized patients in the German statutory notification data of the same time period. Descriptive methods and Poisson regression models were used. Results: Overall, 6672 hospitalized patients from LEOSS and 132,943 hospitalized cases from the German statutory notification data were included. In LEOSS, patients above 76 years were less likely represented (34.3% vs. 44.1%). Moreover, mortality was lower (14.3% vs. 21.5%) especially among age groups above 66 years. Factors associated with a severe COVID-19 disease course in LEOSS included increasing age, male sex (adjusted risk ratio (aRR) 1.69, 95% confidence interval (CI) 1.53–1.86), prior stem cell transplantation (aRR 2.27, 95% CI 1.53–3.38), and an elevated C-reactive protein at day of diagnosis (aRR 2.30, 95% CI 2.03–2.62). Conclusion: We identified a broad range of factors associated with severe COVID-19 progression. However, the results may be less applicable for persons above 66 years since they experienced lower mortality in the LEOSS dataset compared to the statutory notification data.

UR - https://www.scopus.com/pages/publications/85147895540

UR - https://www.mendeley.com/catalogue/fb994041-5f9b-36f3-9184-c96933c3004d/

U2 - 10.1186/s12879-023-08035-z

DO - 10.1186/s12879-023-08035-z

M3 - Journal articles

C2 - 36765274

AN - SCOPUS:85147895540

SN - 1471-2334

VL - 23

SP - 89

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

IS - 1

M1 - 89

ER -

Disease severity in hospitalized COVID-19 patients: comparing routine surveillance with cohort data from the LEOSS study in 2020 in Germany

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

Coronavirus-Bezug

Dokumente

Weitere Links

Fingerprint

Zitieren